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Aim: In this study, chlorhexidine hexametaphosphate (CHX-HMP) is investigated as a 
persistent antimicrobial coating for wound care materials. Materials & methods: CHX-
HMP was used as a wound care material coating and compared with chlorhexidine 
digluconate materials with respect to antimicrobial efficacy, toxicity and wound 
closure. Results: Antimicrobial efficacy at day 1, 3 and 7 was observed with experimental 
and commercial materials. CHX-HMP coated materials had less toxic effect on human 
placental cells than commercial chlorhexidine dressings. CHX-HMP in pluronic gel did 
not delay healing but reduced wound colonization by E. faecalis. Conclusion: CHX-
HMP could become a useful component of wound care materials with sustained 
antimicrobial efficacy, lower toxicity than chlorhexidine digluconate materials, and 
reduction in wound colonization without affecting closure.
First draft submitted: 2 March 2016; Accepted for publication: 17 May 2016; Published 
online: 28 July 2016
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Venous catheters facilitate access to the 
circulatory system for monitoring, drug 
delivery and nutritional support, but are at 
risk of colonization by pathogenic bacteria. 
Infection is initially local, but may become 
systemic via the bloodstream, causing a cath-
eter-related bloodstream infection (CRBSI). 
Incidence varies according to the condition 
that requires the use of a venous catheter and 
many other factors, but it has been reported 
that between 7 and 26% of venous catheter 
users with a range of different underlying 
conditions develop CRBSI [1–4]. CRBSI has 
many adverse clinical consequences; hospi-
tal stay is likely to be extended and there is 
a small but significant increase in absolute 
mortality of intensive care patients of 1% [5]. 
There is also, of course, a financial cost: 
CRBSI carries a cost of $6–60k per event 
and often results in the premature removal of 
the catheter [6–8].
Wound care materials are used at the entry 
site of the catheter to hold the catheter in 
position and, potentially, to protect against 
infection. Catheter entry site dressings are 
traditionally either dry gauze and tape, or 
polyurethane-based materials [9]. The latter 
offer benefits such as clear visibility of the 
catheter entry site, improved durability and 
adhesive properties. Concerns have been 
raised, however, that polyurethane-based 
dressings maintain a high level of humidity at 
the entry site, and that this might contribute 
to a greater risk of colonization by microor-
ganisms, and thus CRBSI [9]. Chlorhexidine 
(CHX)-impregnated dressings may be used 
to reduce this risk. CHX, most commonly 
used as the soluble salt CHX digluconate 
(CHXdg), is a broad spectrum biocide, effi-
cacious against a wide range of Gram-nega-
tive and -positive bacteria, including those 
implicated in CRBSI.
The aim of the study described here is the 
development of a prototype catheter dressing 
that incorporates particles of chlorhexidine 
hexametaphosphate (CHX-HMP). CHX-
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HMP is a sparingly soluble salt of CHX which forms, 
as a nanoparticulate salt, on reaction in water. When 
applied as a coating or dopant for biomaterials, it dis-
solves slowly in aqueous solutions and can thus pro-
vide sustained release of soluble CHX [10–12]. Here, 
CHX-HMP is used as a coating for a catheter entry site 
dressing, and its ability to inhibit bacterial growth is 
assessed, as well as its toxicological potential compared 
with CHXdg, and the effect of the material on wound 
closure and wound infection in mice. The aim of this 
study was to investigate whether these CHX-HMP 
represent a viable option as a functional component for 
antimicrobial wound care materials.
Materials & methods
Preparation of functionalized wound dressings
CHX-HMP was prepared by mixing 10 mM aqueous 
solutions of CHXdg and sodium hexametaphosphate 
using autoclaved deionized water at room temperature 
and pressure under ambient conditions and rapid stir-
ring. Characterization of this CHX-HMP nanopartic-
ulate precipitate has been reported in a previous publi-
cation by our group [10].
The starting wound dressing materials for microbi-
ology experiments were Tegaderm +Pad™ and Tega-
derm CHG™ (both 3M PLC, Bracknell, UK). Tega-
derm +Pad is an adhesive dressing with a pad of dry, 
woven material in the center that contacts the wound. 
Tegaderm CHG is a transparent adhesive dressing with 
a pad of a gel material that contains 2% CHXdg which 
contacts the wound. For each of the dressings, the cen-
tral wound-contacting material was separated from the 
adhesive surrounding panel and sectioned into 10 × 
10 mm portions for use in the experiments, and the 
adhesive mounting material was discarded.
Two dressings were assessed as supplied: Tegaderm 
CHG as a positive control (T-CHG) and Tegaderm 
+Pad as a negative control (T-CTRL). Two proto-
type dressings were prepared: Tegaderm +Pad which 
was immersed for 30 s in a stirred suspension of 5 
mM CHX-HMP followed by a 10 s rinse in deion-
ized water (P-CHX-HMP) and Tegaderm +Pad which 
was immersed for 30 s in a stirred solution of 25 μM 
CHXdg followed by a 10 s rinse in deionized water 
(P-CHG). 25 μM is the residual concentration of aque-
ous CHX that is found in the 5 mM CHX-HMP prep-
aration, thus the P-CHG dressing has been exposed to 
the same soluble CHX as the P-CHX-HMP dressing 
but without the CHX bound in the solid CHX-HMP 
precipitate.
T-CHG absorbed water rapidly on contact with cul-
ture medium and was therefore unsuitable for use as a 
positive control in the toxicology studies. In this phase 
of the experimental work, an alternative commercial 
wound dressing containing 0.5% CHX diacetate was 
used: Bactigras (BAC; Smith and Nephew, Hull, UK) 
and compared with T-CTRL and P-CHX-HMP.
Antimicrobial efficacy
Staphylococcus aureus (EMRSA-15 and methicillin sen-
sitive S. aureus), Pseudomonas aeruginosa (ATCC9027 
and PA14, a highly virulent, multidrug resistant 
wound isolate), Klebsiella pneumoniae (ATCC10031), 
Acinetobacter baumanii (121J6), Escherichia coli 
(NCTC10418) and Staphylococcus epidermidis were 
routinely cultured in nutrient broth (Sigma Aldrich) 
aerobically at 37°C. Clostridium difficile was cultured 
in tryptone soya broth (Sigma Aldrich) under anaero-
bic conditions (DW Scientific anaerobic cabinet) at 
37°C.
Wound dressings T-CHG, T-CTRL, P-CHG and 
P-CHX-HMP were compared with regard to antimi-
crobial efficacy immediately after preparation, after 
7 days aging by immersion, and after 3 days aging 
under flow conditions, to investigate the efficacy of the 
wound dressings several days after it had been applied 
to the wound. To age the dressings by immersion, 
they were immersed in simulated wound fluid (SWF; 
50% v/v fetal calf serum in maximum recovery dilu-
ent; Sigma Aldrich) for 7 days at room temperature 
under aerobic conditions. To age the dressings under 
flow conditions, they were placed in a sterile glass tube 
and SWF flowed over them for 3 days at 0.74 ml/min 
(Watson Marlow 505U peristaltic pump).
Dressings were aseptically transferred into the well of 
a 24 well microtiter plate and submerged in 1 ml SWF. 
Each well was inoculated with the appropriate micro-
organism at 1.5 × 108 cfu/ml and incubated at 37°C for 
16 h under aerobic conditions. Dressings were removed 
from the wells using sterile forceps and transferred into 
sterile plastic bijoux (Fisher Scientific) containing 1 ml 
sterile phosphate buffered saline (Sigma Aldrich) and 
vortexed for 60 s to dislodge bacteria. Serial dilutions 
from 10-1 to 10-12 were prepared in sterile phosphate 
buffered saline and plated onto nutrient agar. Bacteria 
were enumerated using the method of Miles et al. [13]. 
For C. difficile the experiments described above were 
undertaken using an anaerobic cabinet (DW  Scientific) 
and enumeration used tryptone soya agar.
Swabs were processed to maximize the recovery of 
aerobic and facultatively anaerobic bacteria of the skin 
and enteric origin, as typically colonize wounds. Each 
swab was cultured on nutrient agar (for microscopy), 
Blood agar, MacConkeys agar, Baird Parker agar and 
Mannitol Salt agar (all sourced from Sigma Aldrich) 
aerobically at 37°C for 24 h. Pure culture colonies 
were Gram stained, catalase testing was performed 
for Gram positive cocci and oxidase testing performed 
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for Gram negative rods. Presumptive Streptococci spp. 
were further analyzed by Streptex (Remel; UK) test-
ing; presumptive Staphylococci were further analyzed 
by  Staphaurex test (Remel; UK).
Toxicology assays
Reagents were Dulbecco’s modified Eagle medium/
nutrient F-12 Ham (DMEM-F12) (supplemented 
with 1% (v/v) L-glutamine-penicillin-streptomycin 
(PSLG), 1% (v/v) amphotericin B solution (Amp B), 
and 10% (v/v) fetal bovine serum, phosphate buffered 
saline, 0.25% trypsin-EDTA solution (Sigma-Aldrich, 
UK). Wound dressings examined were T-CTRL, 
P-CHX-HMP and BAC.
The placental choriocarcinoma cell line BeWo b30 
was obtained from Prof. Harry McArdle (Rowett 
Research Institute, Aberdeen) with permission from 
Dr. Alan Schwartz (Washington University, MO, 
USA) [14]. Cells were cultured in 5% CO
2
 at 37°C in 
a humidified atmosphere in complete DMEM-F12 
medium with supplements. At confluence, the cells 
were subcultured using 0.25% trypsin-EDTA solution.
BeWo b30 cells were seeded at 1.75 × 105 cells/ml in 
12 well cell culture plates in 1 ml volumes (Corning 
Costar, Sigma-Aldrich, UK), and grown until approxi-
mately 70% confluent (72 h post-seeding). Cells were 
washed with 1 ml fresh medium, and incubated at 
37°C, 5% CO
2
 in a humidified atmosphere for 1 h prior 
to treatment. Cells in 1 ml fresh cell culture medium 
were exposed to T-CTRL, T-CHX-HMP and BAC 
with unexposed cells as a negative control and cells 
exposed to 30% (1 mM) H
2
O
2
 prepared in cell culture 
medium as a positive control. Cells were exposed for 2 
and 24 h to all treatments for toxicity testing.
Cytotoxicity was measured by monitoring the 
release of lactate dehydrogenase (LDH) in the cell 
culture medium from unexposed cells, the positive 
control cells or treated cells which had been exposed 
to CHX-HMP-NP functionalized specimens, using 
the CytoTox 96® nonradioactive cytotoxicity assay 
kit (Promega, Southampton, UK). The assay was per-
formed as per the manufacturer’s instructions.
Briefly, after 2 and 24 h, cell culture supernatants 
were collected and 50 μl aliquots were transferred to 
a flat bottom 96 well plate (Corning Costar, Sigma-
Aldrich, UK). 50 μl of reconstituted assay buffer was 
added to each well containing the specimens, and 
plates were incubated in the dark for 30 min at room 
temperature. 50 μl of the ‘stop solution’ that forms 
part of the CytoTox 96 cytotoxicity assay kit was then 
added to each well, and the plates were read in a mul-
tiwell plate reader (SpectraMax M Series Multi-Mode 
Microplate Reader, Molecular Devices, CA, USA) at 
492 nm. Optical density (OD) readings from wells 
containing cells exposed to treatment were expressed 
as a percentage of the untreated negative control:% of 
control = OD treated/OD untreated × 100.
Data are presented as mean ± SD of three inde-
pendent experiments. Two-way analysis of variance 
(ANOVA) followed by Tukey post hoc multiple com-
parisons test was performed (GraphPad Prism version 
6.00 for Windows, GraphPad Software, CA, USA). 
p < 0.05 was considered significant.
Wound healing in mice
Animal experiments were performed in accordance 
with Home Office regulations described by the UK 
Animals (Scientific Procedures) Act 1986. Three-
month old C57BL/6J mice were anesthetized by isoflu-
orane inhalation and two pairs of full-thickness 4 mm 
excisional punch wounds were made either side of the 
dorsal midline of the barbered back of each animal. 
30% pluronic gel (Sigma) preparations containing no 
additive, 30% pluronic gel with 50 μM EHT1864 
(Sigma Aldrich) or 30% pluronic gel with 5 mM 
CHX-HMP particles were prepared as a liquid at 4°C. 
Appropriate pluronic gel preparations were admin-
istered directly to the wound by pipette immediately 
after wounding and allowed to solidify.
Wound size was recorded by photographing mice at 
the same time each day after wounding. At 2, 3 and 
4 days post wounding, wounds were swabbed with 
Transwab Amies (MWE) for microbiological analysis.
Results
Antimicrobial efficacy
Log
10
 colony forming units (CFU/ml) of the nine 
microbes when exposed for 24 h to T-CTRL, P-CHG, 
P-CHX-HMP and T-CHG dressings after three aging 
conditions are shown, with standard errors, in Table 1. 
All bacteria grew readily in contact with T-CTRL. 
P-CHG caused a small reduction in growth of some 
species, particularly the Staphylococci species and E. 
coli. P-CHX-HMP eliminated microbial growth of 
all but one microorganism; for A. baumanii P-CHX-
HMP resulted in 5 × log
10
 reduction in CFU. T-CHG 
eliminated growth of all bacteria tested. Aging of the 
dressings had no significant effect on the bactericidal 
efficacy of T-CHG or P-CHX-HMP.
Toxicology assays
LDH release from BeWo cells exposed to T-CTRL, 
P-CHX-HMP and BAC is shown in Figure 1. Cells 
exposed to T-CTRL and P-CHX-HMP showed no 
difference in LDH release after 2 and 24 h compared 
with the negative control (media). BAC resulted in an 
LDH release similar to the positive control (H
2
O
2
) 
after 2 and 24 h exposure.
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Wound healing in mice
Relative wound area as a function of time is shown in 
Figure 2, and photographs of the wounds on successive 
days are shown in Figure 3. The proportion of wounds 
testing positive for E. faecalis is shown in Figure 4. 
Application of pluronic gel containing the Rac1-inhib-
itor, EHT-1864, that inhibits signaling downstream 
of growth factors and extracellular matrix, retarded 
wound closure compared with pluronic gel alone, as 
previously observed [15]. Wounds treated with pluronic 
gel containing CHX-HMP were indistinguishable 
from wounds treated with pluronic gel alone.
Microbiological analysis of swabs of the wounds 
revealed that wounds treated with pluronic gel alone 
were contaminated with Enterococcus faecalis at days 
3–5 post-wounding (Figure 3). However, application of 
CHX-HMP in the pluronic gels impaired colonization 
over that time period, supporting the in vitro assess-
ment of wound dressing efficacy in which the growth 
of Gram positive bacteria was inhibited.
Discussion
It is well established that CHX-impregnated catheter 
dressings reduce the incidence of CRBSI [16]. A meta-
analysis of nine randomized clinical trials indicated 
that the use of CHX dressings reduced both catheter 
bacterial colonization and CRBSI [17]. Despite the 
higher cost of CHX dressings, it has been estimated 
that the clinical benefits would be such that adoption 
of CHX dressings for catheter care would result in a 
Table 1. Log10 colony forming units (CFUs) of nine microbes when exposed to four dressings after 
three aging conditions, with standard errors in parentheses.
Microbe Aging Log10 CFU (SE)
  T-CTRL P-CHG P-CHX-HMP T-CHG 
S. epidermidis None 8.17 (0.04) 3.01 (0.01) 0 0
 7 days’ immersion 8.27 (0.03) 3.06 (0.02) 0 0
 3 days’ flow 8.29 (0.03) 3.12 (0.01) 0 0
S. aureus (MSSA) None 8.25 (0.03) 3.03 (0.01) 0 0
 7 days’ immersion 8.31 (0.01) 3.11 (0.00) 0 0
 3 days’ flow 8.26 (0.01) 3.19 (0.01) 0 0
S. aureus (MRSA) None 8.89 (0.28) 3.08 (0.00) 0 0
 7 days’ immersion 8.66 (0.24) 3.21 (0.04) 0 0
 3 days’ flow 8.71 (0.22) 3.32 (0.08) 0 0
P. aeruginosa None 8.86 (0.02) 7.74 (0.01) 0 0
 7 days’ immersion 9.06 (0.15) 7.73 (0.02) 0 0
 3 days’ flow 8.98 (0.16) 7.75 (0.02) 0 0
P. aeruginosa (MDR) None 8.78 (0.03) 7.65 (0.01) 0 0
 7 days’ immersion 8.74 (0.02) 7.67 (0.01) 0 0
 3 days’ flow 8.72 (0.01) 7.67 (0.01) 0 0
K. pneumoniae None 8.40 (0.03) 7.69 (0.00) 0 0
 7 days’ immersion 8.59 (0.04) 7.53 (0.08) 0 0
 3 days’ flow 8.64 (0.04) 7.51 (0.01) 0 0
E. coli None 8.42 (0.18) 0 0 0
 7 days’ immersion 8.66 (0.06) 4.83 (0.04) 0 0
 3 days’ flow 8.64 (0.08) 4.91 (0.04) 0 0
C. difficile None 6.23 (0.01) 4.68 (0.04) 0 0
 7 days’ immersion 6.29 (0.03) 6.01 (0.20) 0 0
 3 days’ flow 6.36 (0.04) 6.11 (0.09) 0 0
A. baumanii None 10.48 (0.01) 7.36 (0.03) 4.80 (0.04) 0
 7 days’ immersion 10.56 (0.03) 7.47 (0.02) 5.04 (0.12) 0
 3 days’ flow 10.62 (0.03) 7.48 (0.01) 5.11 (0.05) 0
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Figure 1. Lactate dehydrogenase (LDH) release from BeWo cells exposed to three wound dressings (T-CTRL, 
P-CHX-HMP and BAC), media (negative control) and H2O2 (positive control) for 2 and 24 h.
0
1000
2000
3000
%
 L
D
H
 r
el
ea
se
d
T-CTRL P-CHX-HMP BAC Media H2O2
5000
4000
2 h
24 h
Figure 2.  Relative wound area in mice treated with pluronic gel (control), pluronic gel with CHX-HMP and 
pluronic gel with the wound healing inhibitor EHT-1864.
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saving of £73 per patient or £4.2–10.8 million per 
year in the UK [18]. Consequently, a CHX-impreg-
nated dressing (Tegaderm CHG) was recommended 
for patients by the National Institute for Health and 
Clinical Excellence (NICE) in the UK in 2015 for high 
dependency patients and those in intensive care [19].
A number of other approaches to creating CHX-
containing dressings have been reported in the litera-
ture. There is particular interest in creating dressings 
which confer a sustained CHX-rich environment. 
CHX diacetate is often the preferred option in these 
experimental dressings, perhaps as it has a lower solu-
bility than CHXdg and thus is selected on the basis 
that this might prolong the CHX release. CHX diace-
tate was incorporated into thermoresponsive polymer 
hydrogels and these offered a degree of sustained CHX 
release, although this persisted for only 2–24 h [20]. 
CHX diacetate was also incorporated into a multilay-
ered polymeric dressing, creating a release profile that 
was sustained for at least 8 days and showing bacte-
riostatic and, at higher concentrations, bactericidal 
 efficacy against S. aureus [21].
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Figure 3. Photographs of wounds on mice on successive days. Column 1: control; column 2: CHX-HMP; 
column 3: EHT 1864, a wound healing inhibitor.
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The approach described here utilized CHX-poly-
phosphate particles, specifically the hexametaphos-
phate salt of CHX. It is already known that these 
gradually dissolve in aqueous environments, provid-
ing a sustained release of soluble CHX, but they have 
not previously been applied for use in wound care. 
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Figure 4. Proportion of mouse wounds infected with E. faecalis as a function of time and gel composition (control 
or CHX-HMP).
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An equivalent antimicrobial efficacy to a commercial 
CHX-based catheter entry site dressing was demon-
strated, with the exception of A. baumanii for which 
the commercial dressing was more efficacious. Both 
the commercial and experimental dressing exhibited 
 bactericidal  efficacy initially and after 3 or 7 days’ 
 ageing.
The cytotoxicity of CHXdg is well established, and 
is dose dependent. CHXdg exhibits cytotoxic effects 
against HaCaT keratinocytes at concentrations of 
0.5% (by mass of the CHX ion, hence 1.0 mM) and 
above [22]. 0.2% (2.2 mM) chlorhexidine digluconate 
exhibited cytotoxic effects against human gingival 
fibroblasts and SaOS2-like cells [23]. It was not possible 
to use the Tegaderm CHG material as the control in 
this study, as the extremely hygroscopic material rap-
idly absorbed all of the culture medium; it was for this 
reason that a different commercial CHX containing 
dressing (Bactigras) was used which did not exhibit 
this behavior. The LDH release assay demonstrated 
that CHX-HMP coated wound dressings exhibited 
lower toxicity than the commercial CHX containing 
dressing; the CHX-HMP dressing was comparable to 
the negative control.
Healing rate could potentially be affected by both 
material toxicity and reduced microbial load in the 
wound. Inflammation is the initial phase of wound 
healing [24]. In addition to combating infection, infil-
trating inflammatory cells secrete growth factors, extra-
cellular matrix, reactive oxygen species and nitric oxide 
that drive the subsequent phases of wound contraction 
and re-epithelialization [24,25], so that modification of 
the wound flora could have a knock-on effect on heal-
ing rates. Pluronic gel was used as a carrier medium for 
the CHX-HMP to examine the effect of CHX-HMP 
on wound healing rates; this was a convenient medium 
as it solidifies at room temperature, which prevents the 
mouse from removing the gel from the wound. Wounds 
treated with gel containing CHX-HMP were indistin-
guishable from those coated with unmodified gel in 
terms of healing time, but exhibited less E. faecalis, with 
this microbe eliminated at 5 days post wounding. Thus 
the CHX-HMP did not adversely affect wound heal-
ing, suggesting in these terms a biocompatible material, 
and it did reduce wound infection, which may provide 
benefit in terms of the development of pathological 
infection at catheter entry sites.
Conclusion
In conclusion, wound dressings coated with CHX-
HMP exhibited a similar antimicrobial profile to a 
commercial CHXdg containing wound care mate-
rial for microbes MRSA, E. coli, K. pneumoniae and 
P. aeruginosa, but for A. baumanii the antimicrobial 
efficacy was less with the prototype material, although 
there was still a 5 × log 10 reduction in colony form-
ing units. Damage to human BeWo cells, as assessed 
by LDH release inferring membrane integrity, was 
not observed with CHX-HMP whereas a commercial 
CHX containing dressing elicited a similar response 
in the cells to the hydrogen peroxide positive control. 
Wound closure in mice was not adversely affected by 
CHX-HMP, but wound colonization by E. faecalis 
was reduced by CHX-HMP. Therefore we conclude 
that CHX-HMP is an effective antimicrobial agent in 
in vivo situations but does not have a negative effect on 
wound healing.
Future perspective
Multifunctional wound dressings are the subject of 
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intensive research, and chief among these are anti-
infective dressings. These functional biomaterials are 
of huge potential clinical impact, allowing physicians 
to prevent infection, and also treat infection which is 
already established. Nanoparticles offer much poten-
tial in this initiative, not least because their small size 
and high surface area can facilitate careful control of 
dose and duration of the antimicrobial agents used. In 
this age of burgeoning antimicrobial resistance, strate-
gies which reduce or negate the need for antibiotics are 
likely to find increasing attention.
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Executive summary
Preparation of wound dressings
•	 Chlorhexidine-hexametaphosphate (CHX-HMP) is a sparingly soluble salt of the widely used biocide 
chlorhexidine, and is formed rapidly as a nanoparticulate salt on combination of the aqueous solutions of the 
component ions.
•	 Commercial wound care materials were coated with CHX-HMP and compared with commercial materials 
containing chlorhexidine digluconate (CHXdg) as well as unmodified dressings.
Antimicrobial efficacy
•	 Both the CHX-HMP and the CHXdg dressings exhibited good antimicrobial efficacy at 1, 3 and 7 days’ aging.
•	 The only substantive difference in antimicrobial performance was with microbe Acenitobacter baumanii, for 
which the commercial CHXdg dressing eliminated bacterial growth but the CHX-HMP dressing, did not, and 
rather resulted in a 5 × log 10 reduction in colony forming units.
Toxicology
•	 CHX-HMP coated dressings exhibited no deleterious effects toward human placental BeWo cells.
•	 A commercial CHXdg dressing did adversely affect the BeWo cells, giving a similar protein release to the 
positive control, hydrogen peroxide.
Wound healing in mice
•	 CHX-HMP applied in pluronic gel to mouse skin wounds had no impact on time to wound closure.
•	 Wounds treated with the CHX-HMP gel exhibited less colonization by E. faecalis.
Conclusion
•	 CHX-HMP provided effective antimicrobial control over at least 7 days, but did not adversely affect human 
placental cells, whereas a CHXdg dressing did.
•	 CHX-HMP did not adversely affect wound healing in mice, but did reduce colonization of the wound by 
E. faecalis.
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